- Home
- ALZN vs KPRX Comparison
ALZN vs KPRX Comparison
Compare ALZN & KPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALZN
- KPRX
- Stock Information
- Founded
- ALZN 2016
- KPRX 1998
- Country
- ALZN United States
- KPRX United States
- Employees
- ALZN 7
- KPRX N/A
- Industry
- ALZN Medicinal Chemicals and Botanical Products
- KPRX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- ALZN Health Care
- KPRX Health Care
- Exchange
- ALZN Nasdaq
- KPRX Nasdaq
- Market Cap
- ALZN 9.0M
- KPRX 9.2M
- IPO Year
- ALZN 2021
- KPRX N/A
- Fundamental
- Price
- ALZN $2.44
- KPRX $2.48
- Analyst Decision
- ALZN Strong Buy
- KPRX Strong Buy
- Analyst Count
- ALZN 1
- KPRX 1
- Target Price
- ALZN $42.00
- KPRX $10.00
- AVG Volume (30 Days)
- ALZN 132.0K
- KPRX 48.4K
- Earning Date
- ALZN 12-11-2025
- KPRX 11-07-2025
- Dividend Yield
- ALZN N/A
- KPRX N/A
- EPS Growth
- ALZN N/A
- KPRX N/A
- EPS
- ALZN N/A
- KPRX N/A
- Revenue
- ALZN N/A
- KPRX N/A
- Revenue This Year
- ALZN N/A
- KPRX N/A
- Revenue Next Year
- ALZN N/A
- KPRX N/A
- P/E Ratio
- ALZN N/A
- KPRX N/A
- Revenue Growth
- ALZN N/A
- KPRX N/A
- 52 Week Low
- ALZN $2.06
- KPRX $2.21
- 52 Week High
- ALZN $15.21
- KPRX $4.18
- Technical
- Relative Strength Index (RSI)
- ALZN 52.35
- KPRX 43.65
- Support Level
- ALZN $2.32
- KPRX $2.21
- Resistance Level
- ALZN $2.53
- KPRX $2.65
- Average True Range (ATR)
- ALZN 0.14
- KPRX 0.15
- MACD
- ALZN 0.01
- KPRX -0.01
- Stochastic Oscillator
- ALZN 69.83
- KPRX 48.42
About ALZN Alzamend Neuro Inc.
Alzamend Neuro Inc is an early clinical-stage biopharmaceutical company. It is focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer's. Its mission is to develop and market safe and effective treatments. The company's pipeline consists of two novel therapeutic drug candidates, AL001 - a patented ionic cocrystal technology delivering lithium via a therapeutic combination of lithium, proline and salicylate, and AL002 - a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient's immunological system to combat Alzheimer's.
About KPRX Kiora Pharmaceuticals Inc.
Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.